RecruitingNot ApplicableNCT06629207

Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder

Artificial Intelligence on Molecular Imaging to Predict the Risks of Parkinson's Disease for Patients With Rapid Eye Movement Sleep Behavior Disorder

Sponsor

Insel Gruppe AG, University Hospital Bern

Enrollment

20 participants

Start Date

Oct 7, 2024

Study Type

INTERVENTIONAL

Conditions

Parkinson Disease REM Sleep Behavior Disorder Dementia, Lewy Body

Summary

The study aims to systematically document the course of REM sleep behavior disorder (RBD) and investigate possible clinical and imaging biomarkers for disease progression and conversion risk to Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). The study will use artificial intelligence to analyze imaging and develop a reliable method to predict and stratify patients approaching conversion to overt a-synucleinopathy. Participants will be clinically evaluated and 2 imaging procedures will be done.

Eligibility

Min Age: 18 Years

Inclusion Criteria2

Confirmed clinical iRBD diagnosis by movement disorder specialists according to the International Classification of Sleep Disorders
Written informed consent

Exclusion Criteria5

Known diagnosis of PD or other neurodegenerative disorder
Unequivocal signs of parkinsonism on examination
Narcolepsy or other known causes of RBD
Moderate to severe obstructive sleep apnea
Abnormal neurological or MRI examination

Interventions

DEVICEPET/CT with 18-FDG

FDG-PET scans will be acquired in a Siemens Biograph Vision Quadra PET/CT (Siemens, Germany) at 30-minute post-injection of approximately 80 MBq 18F-FDG. The duration of the acquisition is 20 minutes. The PET images will be reconstructed with the vendor's time of flight (TOF) point-spread-function (PSF) algorithm, following corrections for randoms, scatter, and decay. Attenuation correction will be performed first using low-dose CT.

DEVICESPECT : 123 I-FP-CIT (DATSCAN)

DaT-Scans will be acquired in a GE Discovery NM/CT 670 Pro™. After injection of approximately 110 MBq 123I-FP-CIT, images will be acquired within 4 h post-injection. The duration of the acquisition is 35 minutes.

DEVICEMRI

MRI examination to exclude structural brain anomalies.